Common use of Collaborative Development Clause in Contracts

Collaborative Development. Magainin will supply to this collaboration its Know How, scientific findings and other research showing the IL-9 mechanism and its role in modulating allergic and asthmatic response to antigen. Genentech and Magainin will conduct the Initial Research, including certain proof of concept relating to the IL-9 mechanism in respiratory/immune reaction to antigen, as determined by the Joint Project Team and provided in the Joint Development Plan. In addition to which, Genentech wishes to develop a human or humanized Antibody (using Genentech proprietary Know How or a transgenic mouse), as well as possibly generate a mouse Antibody that reacts with or affects IL-9 or IL-9 receptors. The Initial Research shall begin on the Effective Date and last until such time that the Joint Project Team selects the Compound for clinical development, including Phases I and II testing by Magainin. All such Initial Research shall be conducted by the Parties together or individually as assigned to tasks by the Joint Project Team, at the sole expense of the Party completing the work and at -------------------------------------------------------------------------------- **Certain portions of this exhibit have been omitted based upon a request for confidential treatment that has been filed with Commission. The omitted portions have been filed separately with the Commission. Magainin's expense for Phases I and II Clinical Studies. Once the data from those trials merits the commencement of a Phase III Clinical Study (per the determination by the Joint Project Team), Genentech shall at its expense (subject only to Section 8.6 herein), design the Phase III Clinical Study and take the Compound into Phase III, or a pivotal trial, through and including filing of the NDA/BLA. Genentech will be responsible for manufacturing Compounds hereunder. Magainin may have a role in manufacturing (or contract manufacturing) Small Molecule Compounds if so decided by the Joint Project Team and approved by the JSC. In accordance with the JSC approved budget for the Collaboration Program, Genentech will provide quarterly funding in advance for Magainin Collaboration Program expenses with preferred equity in tranches of that same Series A equity provided in the Stock Purchase Agreement, of even date herewith.

Collaborative Development. Magainin will supply to this collaboration its Know How, scientific findings and other research showing the IL-9 mechanism and its role in modulating allergic and asthmatic response to antigen. Genentech and Magainin will conduct the Initial Research, including certain proof of concept relating to the IL-9 mechanism in respiratory/immune reaction to antigen, as determined by the Joint Project Team and provided in the Joint Development Plan. In addition to which, Genentech wishes to develop a human or humanized Antibody (using Genentech proprietary Know How or a transgenic mouse), as well as possibly generate a mouse Antibody that reacts with or affects IL-9 or IL-9 receptors. The Initial Research shall begin on the Effective Date and last until such time that the Joint Project Team selects the Compound for clinical development, including Phases I and II testing by Magainin. All such Initial Research shall be conducted by the Parties together or individually as assigned to tasks by the Joint Project Team, at the sole expense of the Party completing the work and at -------------------------------------------------------------------------------- ________________________________________________________________________________ *** Certain portions of this exhibit have been omitted based upon a request for confidential treatment that has been filed with the Commission. The omitted portions have been filed separately with the Commission. Magainin's expense for Phases I and II Clinical Studies. Once the data from those trials merits the commencement of a Phase III Clinical Study (per the determination by the Joint Project Team), Genentech shall at its expense (subject only to Section 8.6 herein), design the Phase III Clinical Study and take the Compound into Phase III, or a pivotal trial, through and including filing of the NDA/BLA. Genentech will be responsible for manufacturing Compounds hereunder. Magainin may have a role in manufacturing (or contract manufacturing) Small Molecule Compounds if so decided by the Joint Project Team and approved by the JSC. In accordance with the JSC approved budget for the Collaboration Program, Genentech will provide quarterly funding in advance for Magainin Collaboration Program expenses with preferred equity in tranches of that same Series A equity provided in the Stock Purchase Agreement, of even date herewith.